BDNF and myeloid sarcoma: In a mouse model of MS, it was demonstrated that IF ameliorated the clinical course of the disease, leading to less inflammation, demyelination, and axonal damage; reversed the EAE-mediated CNS accumulation of total CD4+ T cells; reduced the levels of pro-inflammatory cytokines and Th1 and Th17 cells; increased the number of Tregs; and enhanced the expression of brain-derived neurotrophic factor (BDNF) and remyelination markers (119, 121, 162–164).